Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VP1-targeting small molecule inhibitor
- Development stage
- Preclinical
- Lead developer
- Orthogon Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VP1-targeting small molecule inhibitor is a first-in-class, orally available small molecule antiviral candidate being developed by Orthogon Therapeutics (an affiliate of Pledge Therapeutics) to address BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV) infections. The drug candidate targets the highly conserved intracellular domain of the viral capsid protein VP1, disrupting the viral lifecycle and capsid architecture. This mechanism provides pan-genotypic activity across BKPyV variants and related polyomaviruses, bypassing the limitations of neutralizing monoclonal antibodies that are prone to viral escape due to sequence variation in the outer BC-loop. It is designed to penetrate renal sanctuaries of viral replication and is being developed for the prevention and treatment of BKPyV reactivation, viruria, viremia, nephropathy, and hemorrhagic cystitis in kidney and hematopoietic transplant recipients.
- Other names
- BK polyomavirus VP1 inhibitorcapsid protein VP1 inhibitorVP1-targeting small molecule therapeuticVP-1-targeting small molecule therapeuticVP 1-targeting small molecule therapeutic
02
Targets
Norovirus VP1JCV (John Cunningham virus)
Beyond the preview
Go deeper on VP1-targeting small molecule inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VP1-targeting small molecule inhibitor.